Celularity vs Jaguar Health
CELU and JAGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CELU and JAGX compare
Celularity is the larger company, worth 11 times as much as Jaguar Health ($24.4M against $2.3M).
Jaguar Health grew revenue faster over the last twelve months (136% versus −58.1% for Celularity).
Celularity scores higher on the StockData Score (7 against 3 for Jaguar Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CELU | JAGX |
|---|---|---|
| Size and price | ||
| Market cap | $24.4M | $2.3M |
| Share price | $0.751 | $0.440 |
| Change, 1 year | −57.6% | −100.0% |
| Change, 5 years | −98.9% | −100% |
| Beta (5Y) | 1.96 | 2.19 |
| Employees | 115 | 47 |
| StockData Score | ||
| Total score | 7 (better) | 3 |
| Valuation score | 1 | 1 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 4 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.3× | 0.1× (better) |
| Growth | ||
| Revenue growth (TTM) | −58.1% | 136% (better) |
| Revenue growth, 5Y average | 13.2% (better) | 4.2% |
| Profitability | ||
| Gross margin | 19.2% | 82.3% (better) |
| Operating margin | −264% | −93.1% (better) |
| Net margin | −246% | – |
| Financial health | ||
| Interest coverage | – | −25.9× |
| Current ratio | 0.11 | 0.69 (better) |
| Altman Z-score | −16.46 (better) | −18.45 |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 6.8% | – |
| Held by insiders | – | 17.1% |
| Short interest, % of float | – | 4.7% |
Go deeper
- CELU stock overview
- CELU income statement
- CELU valuation and score
- JAGX stock overview
- JAGX income statement
- JAGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.